Despite the proven pivotal role of endogenously produced IFN-γ in anti-tumor immunity in experimental in vivo models, the low response rate to this cytokine in cancer immunotherapy trials might be explained by the resistance of tumor cells to IFN-γ [121,122,214]. The gene discussed is IFNG; the disease is neoplasm.